Current approaches to the treatment of HER2‑positive breast cancer with brain metastases

T.  Yu.  Semiglazova; Семиглазова Т. Ю.; S.  M.  Sharashenidze; Шарашенидзе С. М.; S.  N.  Kerimova; Керимова С. Н.; V.   V. Klimenko; Клименко В. В.; A. Yu.  Malygin; Малыгин А. Ю.; G.  A.  Dashyan; Дашян Г. А.; R.   M. Paltuev; Палтуев Р. М.; V.  V.  Semiglazov; Семиглазов В. В.; P.   V. Krivorotko; Криворотько П. В.; S.  N.  Novikov; Новиков С. Н.; V.   F. Semiglazov; Семиглазов В. Ф.

doi:10.17650/1994-4098-2021-17-1-27-34

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases

Authors: Semiglazova T.Y.¹^,2, Sharashenidze S.M.¹, Kerimova S.N.¹, Klimenko V.V.¹, Malygin A.Y.¹, Dashyan G..¹, Paltuev R.M.¹, Semiglazov V.V.¹^,3, Krivorotko P.V.¹^,2, Novikov S.N.¹, Semiglazov V..¹^,2
Affiliations:
1. N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
3. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Issue: Vol 17, No 1 (2021)
Pages: 27-34
Section: MAMMOLOGY. REVIEWS
Published: 16.06.2021
URL: https://ojrs.abvpress.ru/ojrs/article/view/811
DOI: https://doi.org/10.17650/1994-4098-2021-17-1-27-34
ID: 811

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The article discusses modern approaches in the treatment of HER2-positive breast cancer (BC) with brain metastases (BM).
The patients are subject to multidisciplinary, comprehensive and biologically – oriented treatment, with the involvement of a neurosurgeon and a radiation therapist to make a decision considering local treatment of BM, as well as a clinical oncologist to choose systemic drug therapy. Local treatment of HER2+ BC with BM patients includes surgical treatment and/or radiotherapy. Use of targeted anti-HER2 therapy changes “biology” of the disease from aggressive to indolent.
In the prospective KAMILLA trial, clinically significant antitumor activity of trastuzumab emtansine was found for the first time both in patients with HER2+ BC with BM, who were previously treated with radiotherapy, and without radiotherapy in the anamnesis, which suggests the validity of further use of trastuzumab emtansine in this category of patients.
The antitumor activity of trastuzumab emtansine in patients with HER2+ BC with BM was also confirmed in preclinical models. Despite the similar drug distribution in the tissues, trastuzumab emtansine, in contrast to trastuzumab, significantly slowed the growth of metastases, causing the induction of apoptosis in HER2+ BC models with BM in mice.

Keywords

HER2-positive breast cancer, brain metastases, T-DM1, trastuzumab emtansine, anti-HER2 therapy

About the authors

T. Yu. Semiglazova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia; I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: tsemiglazova@mail.ru
ORCID iD: 0000-0002-4305-6691

Tatyana Yuryevna Semiglazova